Adicet Bio
Clinical trials sponsored by Adicet Bio, explained in plain language.
Clinical-stage biotech developing engineered gamma-delta T cell therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on lupus and scleroderma in early trial Results expected Dec 2026 (estimated)
- Engineered immune cells target CD70 in kidney cancer Results expected Dec 2026 (estimated)
- Engineered immune cells take on stubborn arthritis in early trial Results expected Mar 2027 (estimated)
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingResearchers are testing a new cell therapy called ADI-270 in adults with clear cell renal cell carcinoma that has come back or stopped responding to standard treatments. ADI-270 uses engineered gamma-delta T cells that carry a chimeric receptor to seek out and attack cancer cells…
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control By invitation onlyThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …
Phase 1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
15-Year watch begins for CAR t cell therapy patients
Knowledge-focused OngoingThis study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to be…
Sponsor: Adicet Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC